- Home
- TRC vs TRML Comparison
TRC vs TRML Comparison
Compare TRC & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- TRML
- Stock Information
- Founded
- TRC 1843
- TRML 2021
- Country
- TRC United States
- TRML United States
- Employees
- TRC N/A
- TRML N/A
- Industry
- TRC Real Estate
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- TRML Health Care
- Exchange
- TRC Nasdaq
- TRML Nasdaq
- Market Cap
- TRC 431.4M
- TRML 509.8M
- IPO Year
- TRC N/A
- TRML N/A
- Fundamental
- Price
- TRC $16.26
- TRML $17.88
- Analyst Decision
- TRC
- TRML Strong Buy
- Analyst Count
- TRC 0
- TRML 6
- Target Price
- TRC N/A
- TRML $54.00
- AVG Volume (30 Days)
- TRC 105.5K
- TRML 224.3K
- Earning Date
- TRC 03-05-2025
- TRML 03-18-2025
- Dividend Yield
- TRC N/A
- TRML N/A
- EPS Growth
- TRC N/A
- TRML N/A
- EPS
- TRC N/A
- TRML N/A
- Revenue
- TRC $40,118,000.00
- TRML N/A
- Revenue This Year
- TRC N/A
- TRML N/A
- Revenue Next Year
- TRC $16.57
- TRML N/A
- P/E Ratio
- TRC N/A
- TRML N/A
- Revenue Growth
- TRC N/A
- TRML N/A
- 52 Week Low
- TRC $14.71
- TRML $12.12
- 52 Week High
- TRC $19.82
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- TRC 57.88
- TRML 33.31
- Support Level
- TRC $15.00
- TRML $17.00
- Resistance Level
- TRC $16.45
- TRML $20.08
- Average True Range (ATR)
- TRC 0.36
- TRML 1.24
- MACD
- TRC 0.08
- TRML -0.15
- Stochastic Oscillator
- TRC 86.90
- TRML 16.89
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely commercial/industrial real estate development, resort/residential real estate development, mineral resources, farming, and ranch operations.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.